Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px
Collaboration › Details

Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie

 

Period Period 2019-10-29
Region Region ALL
Organisations Partner, 1st Disc Medicine (US)
  Partner, 2nd AbbVie Inc. (NYSE: ABBV)
  Group AbbVie (Group)
Products Product hemojuvelin antibody
  Product 2 anti-anemic drug
Index term Index term Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S
     

Disc Medicine. (10/29/19). "Press Release: Disc Medicine Expands Pipeline Focused on Hepcidin Pathway. Enters into Exclusive Agreement with AbbVie for Series of Hemojuvelin Antagonist Monoclonal Antibodies". Cambridge, MA.

Disc Medicine, a hematology company that is applying new insights in hepcidin biology to develop therapies addressing ineffective red blood cell production in hematologic diseases, today announced that it has entered into an exclusive license agreement with AbbVie for the worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies. Terms of the license agreement have not been disclosed.

"The addition of these hemojuvelin antagonist antibodies to our pipeline is an excellent strategic fit for Disc Medicine," said Brian MacDonald, founder and interim CEO of Disc Medicine. "Our first program is a novel, orally administered therapy which increases hepcidin expression to treat iron loading anemias. In contrast, these antibodies target hemojuvelin to reduce hepcidin expression and provide us with the opportunity to develop new approaches to the treatment of anemia in a different spectrum of chronic inflammatory and hematologic diseases."

Hepcidin, a small peptide hormone produced in the liver, is the key regulator of iron metabolism that when dysregulated is associated with either iron overload or iron deficiency. Both of these conditions can be associated with ineffective red blood cell production, often leading to severe anemia in a range of hematological and non-hematological diseases that can significantly impact lifespan as well as quality of life.


About Disc Medicine

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

   
Record changed: 2019-10-30

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Disc Medicine (US)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top